CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VIVA Biotech Holdings is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VIVA Biotech Holdings
735 Ziping Road
Zhoupu Town, Pudong New District
Phone: +86 2160893288p:+86 2160893288 Shanghai, SHA  201318  China Ticker: 18731873

Business Summary
VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.
(Source: N-30D)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer Chen CheneyMao 61 7/3/2018 7/3/2018
Chief Financial Officer ZherenWang 39 4/1/2021 4/1/2021
Co-Chief Financial Officer WeiXiong 40 12/1/2023 12/1/2023
12 additional Officers and Directors records available in full report.

Business Names
Business Name
1873
Synthesis Med Chem (Hong Kong)

General Information
Number of Employees: 2,077 (As of 12/31/2023)
Outstanding Shares: 1,926,366,305 (As of 11/13/2023)
Stock Exchange: HKG
Fax Number: +86 2158243936


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024